Previous 10 | Next 10 |
ATLANTA, GA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of Phase 1/2 clinical trial data ...
ATLANTA, GA - ( NewMediaWire ) - June 28, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that an abstract regarding GeoVax’s gene therapy candidate, Gedeptin ® , has be...
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that an abstract regarding GeoVax’s gene therapy candidate...
Spotlight Content on Pandemic Preparedness: Getting Ready for the Next “Disease X” ATLANTA, GA, June 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infe...
ATLANTA, GA - ( NewMediaWire ) - May 31, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced it has executed a Master Services Agreement (MSA) with Advanced Bioscience Laboratories, Inc. ...
Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapie...
2023-05-24 09:12:18 ET GeoVax Labs ( NASDAQ: GOVX ) presents updates on its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial. The presentations at Vaccines Summit Boston 2023 and CYTO 2023 meetings feature unpubl...
New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA - ( NewMediaWire ) - May 24, 2023 - via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company d...
New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and ...
Presentations to Include New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 ATLANTA, GA - ( NewMediaWire ) - May 15, 2023 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...
News, Short Squeeze, Breakout and More Instantly...
ATLANTA, GA - ( NewMediaWire ) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a cert...
GeoVax Labs, Inc. (NASDAQ: GOVX) is one of today's top gainers. The company's shares have moved 20.05% on the day to $3.02. GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ank...
Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s ...